Compare PAI & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAI | CGEN |
|---|---|---|
| Founded | 1973 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.3M | 125.3M |
| IPO Year | N/A | 2000 |
| Metric | PAI | CGEN |
|---|---|---|
| Price | $12.36 | $1.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.0K | ★ 285.4K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $231.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.59 | $1.13 |
| 52 Week High | $12.63 | $2.66 |
| Indicator | PAI | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 39.97 | 41.58 |
| Support Level | $12.36 | $1.47 |
| Resistance Level | $12.44 | $1.72 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 19.05 | 12.00 |
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.